Table 2 Univariate and multivariate analysis for assessing human herpesvirus-6 reactivation factors

Age (years)

0.984 (0.940–1.029)

Gender^c

0.271 (0.061–1.200)

0.261 (0.038–1.779)

Donor sex^c

0.333 (0.023–4.736)

Underlying haematologic disease^c

 AML^c

2.667 (0.506–14.063)

 ALL^c

3.692 (0.305–44.692)

 Biphenotypic acute leukemia^c

–

 Aplastic anaemia^c

–

 HL^c

0.226 (0.024–2.097)

 NHL^c

–

 Multiple Myeloma^c

0.848 (0.231–3.114)

Conditioning regimen

MAC

 Busulfan + cyclophosphamide^c

4.594* (1.052–20.057)

1.915 (0.324–11.328)

RIC

 Cyclophosphamide + fludarabine^c

–

 BEAM protocol^c

0.107* (0.012–0.949)

0.054* (0.003–0.877)

 Melphalan^c

0.848 (0.231–3.114)

Pre-transplant HHV-6 IgG^c

3.50 (0.368–33.308)

Unexplained fever^c

0.615 (0.168–2.252)

Cutaneous rash^c

Thrombocytopenia^c

5.750 (0.950–34.787)

0.584 (0.009–38.014)

Delayed engraftment/bone marrow suppression^c

3.500 (0.791–15.479)

13.239 (0.332–528.126)

Days to platelets engraftment (mean)

0.794 (0.585–1.078)

Days to neutrophils engraftment (mean)

1.064 (0.903–1.253)

aGVHD^c

–